TPST Tempest Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1544227 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.6%
TTM EPS YoY67.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,797.6%
ROA-313.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets120.9%
Debt / equity—
Current ratio0.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $12.61M | $28.48M | $17.50M | $22.53M | $17.17M |
| SG&A expense | $13.97M | $13.55M | $11.66M | $12.11M | $9.82M |
| Operating income | -$26.57M | -$42.03M | -$29.16M | -$34.64M | -$26.99M |
| Interest expense | $207,000 | $1.32M | $1.45M | $1.62M | $1.28M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.26M | -$41.84M | -$29.49M | -$35.71M | -$28.30M |
| EBITDA | -$26.31M | -$41.64M | -$28.78M | -$34.00M | -$26.61M |
| EPS (basic) | -6.33 | -19.50 | -1.91 | -3.09 | -7.47 |
| EPS (diluted) | -6.33 | -19.50 | -1.91 | -3.09 | -7.47 |
| Weighted avg. shares (diluted) | 4.15M | 2.15M | 15.42M | 11.55M | 3.79M |
| Balance sheet | |||||
| Cash & equivalents | $7.71M | $30.71M | $39.67M | $31.60M | $51.83M |
| Current assets | $8.27M | $31.47M | $40.36M | $32.95M | $68.96M |
| PP&E, net | $605,000 | $886,000 | $840,000 | $1.06M | $1.11M |
| Total assets | $16.93M | $41.49M | $51.60M | $46.09M | $73.24M |
| Current liabilities | $3.31M | $14.22M | $9.41M | $7.28M | $20.03M |
| Short-term debt | $0 | $6.35M | $4.29M | — | — |
| Long-term debt | — | $0 | $6.26M | $10.37M | $15.07M |
| Total debt | — | $6.35M | $10.55M | $10.37M | $15.07M |
| Total liabilities | $10.26M | $22.36M | $24.84M | $27.98M | $37.12M |
| Shareholders' equity | $6.67M | $19.13M | $26.77M | $18.11M | $36.12M |
| Net debt | — | -$24.36M | -$29.12M | -$21.23M | -$36.76M |
| Shares outstanding | 4.93M | 3.38M | 22.05M | 10.52M | 6.91M |
| Cash flow statement | |||||
| Operating cash flow | -$26.82M | -$33.03M | -$27.36M | -$31.07M | -$25.96M |
| Capital expenditure | $0 | $435,000 | $170,000 | $562,000 | $135,000 |
| Free cash flow | -$26.82M | -$33.46M | -$27.53M | -$31.63M | -$26.09M |
| Investing cash flow | $0 | -$435,000 | -$170,000 | -$562,000 | -$97,000 |
| Financing cash flow | $4.26M | $24.50M | $35.60M | $11.40M | $59.06M |
| Depreciation & amortization | $266,000 | $389,000 | $381,000 | $638,000 | $374,000 |
| Stock-based compensation | $3.12M | $5.30M | $2.55M | $1.56M | $1.10M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.